Podcasts about Hemostasis

In this very important episode, Dr. Rebecca Dekker is taking a look at the updated evidence on Vitamin K for newborns. Vitamin K deficiency bleeding (VKDB) is a rare but serious condition that can lead to life-threatening complications in infants. Dr. Dekker breaks down what Vitamin K is, why newborns are at risk for VKDB, and the different supplementation options available—including the Vitamin K shot and oral drops. This episode also tackles myths and misinformation surrounding Vitamin K, including concerns about safety, the so-called “gentle birth” exemption, and the controversial "black box warning." Armed with new research, we explore the effectiveness of various oral Vitamin K regimens, and go over the global recommendations for Vitamin K supplementation.   (00:04:01) The Essential Role of Vitamin K for Blood Clotting (00:08:10) Significance of Vitamin K in Newborns' Health (00:14:31) Preventing VKDB: Vitamin K Shot vs Drops (00:16:14) Vitamin K Shot vs. Oral Drops Debate (00:20:00) Effectiveness of Oral Vitamin K Drops vs. Injection (00:31:39) Vitamin K Transfer Through Placental Barrier (00:41:33) Preventing VKDB in Newborns: Pros and Cons of Vitamin K Options   Resources: Read the full-length EBB Signature Article on Vitamin K (includes all scientific references + a FREE 1-page handout!) at https://ebbirth.com/vitaminK EBB Pocket Guide to Newborn Procedures: https://ebbirth.com/shop EBB Childbirth Class: https://ebbirth.com/childbirthclass CDC Real stories: People with Vitamin K. Deficiency Bleeding CDC VKDB information Watch this YouTube video from Dr. Matt and Dr. Mike about Hemostasis and the Clotting Cascade (and why Vitamin K and Calcium are important) International Federation of Library Associations and Institutions: How to Spot Fake News University of Chicago: Evaluating Resources and Misinformation Web Literacy for Student Fact Checkers (and other people who care about facts) For more information about Evidence Based Birth® and a crash course on evidence based care, visit www.ebbirth.com. Follow us on Instagram and YouTube! Ready to learn more? Grab an EBB Podcast Listening Guide or read Dr. Dekker's book, "Babies Are Not Pizzas: They're Born, Not Delivered!" If you want to get involved at EBB, join our Professional membership (scholarship options available) and get on the wait list for our EBB Instructor program. Find an EBB Instructor here, and click here to learn more about the EBB Childbirth Class.

The AZALEA–TIMI 71 trial compared abelacimab, a monoclonal antibody targeting factor XI, with rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk.

Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology-Oncology, and Professor of Pediatrics at Keck School of Medicine at the University of Southern California (USC), is currently serving as co-chair of i3 Health's CME/NCPD activity, Practice-Changing Advances in the Management of Hemophilia. With new developments in the field occurring over recent months, Dr. Young sat down with us to share recent updates in the hemophilia treatment and management. Click the links below for the full activity! Online accredited CME/NCPD activity: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia Accredited CME/NCPD podcast: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia-podcast

Our initial review of the PLATO trial, published in April 2024, was based on the data available to us at that time. We have since became aware of new information that reduces our confidence in the PLATO results. This new information has major implications for clinical practice. Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.Despite representing only 6.9% of the total P2Y12 inhibitor prescriptions among Medicare beneficiaries in 2020, Ticagrelor accounted for nearly two-thirds of total Medicare spending on these drugs in the same year. We summarize important points below but you can refer to this investigation at BMJ for more details.1. Unexplained Regional Variation: In our original review, we highlighted the treatment effect interaction based on region of enrollment, where ticagrelor was less effective compared to clopidogrel for patients enrolled in North America. It appeared to be a strong signal and was associated with a p-value for the interaction of 0.05. However, we were cautious in our interpretation since overall, patients enrolled in North America represented a relatively small fraction of total patients and we could not think of a reasonable explanation.Information in the BMJ investigation now sheds new light on these findings. In our review, we only presented data contained in the supplement accompanying the PLATO trial manuscript, which categorized patients based on region of enrollment but did not provide country specific information. The BMJ report notes that in a separate subgroup analysis, based on country of randomization, the primary outcome was numerically higher with ticagrelor in the United States (12.6% vs 10.1%, HR: 1.27, 95% CI: 0.92 – 1.75). This subgroup represented 7.6% of the total trial participants. Overall, 9.7% of trial participants were enrolled from North America. This means the US data drove the findings from the North American subgroup.The explanation provided by AstraZeneca (the manufacturer of ticagrelor) to explain the observed treatment effect heterogeneity was that aspirin dosing in the United States was higher than in other countries. It even led the FDA to issue a black box warning to avoid an aspirin maintenance dose of >100 mg in patients taking ticagrelor. An extensive statistical analysis of the regional variation in PLATO yielded four interesting points. First what was the prior likelihood of observing a ticagrelor vs clopidogrel HR of > 1.25 in the US, when the overall HR was actually equal to 0.84? That probability is ≤ 0.01. This alone suggests more than chance. Second point: a strong US/nonUS interaction was noted for each of the 3 components of the primary endpoint—CV death, MI, stroke. Third: they found a very strong interaction between treatment and median aspirin dose, and, importantly, the aspirin interaction effect was similar in US and nonUS settings. Fourth, an analysis of contract research organization (CRO) vs sponsor monitoring of the site accounted for 61% of the treatment-by- region interaction. The authors downplayed this finding because of the four countries monitored by a CRO (Israel, US, Georgia and Russia), the US made up the majority and thus is confounded by the aspirin interaction. Noteworthy was a lack of direct analysis of CRO vs sponsor test for interaction. One problem though: the BMJ investigation found that the lead author, Kevin Carroll was the head statistician at AstraZeneca and had worked at the company for 20 years. Carroll presented the PLATO results at the FDA advisory meeting. The paper lists Carroll as having no conflicts. Carroll told the BMJ that he had disposed of all conflicts of interest before submitting that analysis. But, in our opinion, the aspirin explanation does not pass muster because of biologic implausibility. See next section: How would a higher dose of aspirin reduce the efficacy of ticagrelor?The primary composite endpoint was vascular death, MI or stroke. If the higher aspirin dose impacted this, we would hypothesize that it caused more major bleeding in the ticagrelor group with some events resulting in vascular death, type 2 MI and hemorrhagic stroke, driving the treatment effect in favor of clopidogrel. But there is no evidence of this.The figure below is from the original subgroup plots provided in the PLATO supplement. The difference in the treatment effect for the primary endpoint for North American patients is striking but there is no difference for major bleeding.In our opinion and the opinion of others, the role of supervision of the centers could be important. Most centers were monitored by the sponsor. Four countries (Israel, US, Georgia and Russia) were monitored by a contract research organization. All four of these countries had numerically higher rates of the primary outcome in the ticagrelor group. This has major implications and we do not take them lightly. Essentially, it suggests malfeasance on the part of the sponsor. So is there anything else to support such a claim? Well, yes. 2. Concerns about event adjudication. Based on a report from Victor Serebruany, an adjunct faculty member at Johns Hopkins University, and the BMJ investigation, FDA records indicated that site reports documented 504 myocardial infarctions in patients who received ticagrelor compared to 548 in patients who received clopidogrel. However, after adjudication, the count increased only for the clopidogrel group, reaching 593. There was also some imbalance among groups in adjudicating death. These imbalances raise concerns about potential unblinding and result tampering. We read many of the authors' replies and we did not find a clear explanation of why all readjudicated extra MIs were in the clopidogrel group (45 clopidogrel; ticagrelor 0). 3. There were also concerns about the accuracy of death records as sites death records did not always match the FDA records.We cite from the BMJ: The BMJ's analysis also found omissions in PLATO's landmark publication. The paper, published in NEJM and reported as an intent-to-treat analysis, reports 905 total deaths from any cause among all randomized patients. An internal company report states, however, that 983 patients had died at this point. While 33 deaths occurred after the follow-up period, the NEJM tally still leaves out 45 deaths “discovered after withdrawal of consent.” The BMJ obtained some records for patients whose deaths were not reported in NEJM (see table 1) and asked the journal for a response.NEJM editor in chief Eric Rubin told The BMJ that “for older manuscripts, correction is not necessarily appropriate unless there would be an effect on clinical practice,” concluding that “it does not appear that correcting this 15-year-old article is going to have any impact.”It is noteworthy that the United States Department of Justice launched a formal investigation into the PLATO trial in 2013; however, the probe was closed in 2014. The BMJ column cited a spokesperson for the US attorney's office who said…”we determined that the allegations lacked sufficient merit such that it was not in the best interests of the US to intervene in the suit.” 4. Mortality reduction in PLATO defies explanation: Shortly after PLATO was published, Drs. Victor Serebruany and Dan Atar wrote an editorial in the European Heart Journal titled: The PLATO trial: do you believe in magic? They noted that the overall HR for all-cause death ticagrelor vs clopidogrel was 0.78 (95% CI: 0.69 - 0.89; p< 0.001). There were 107 more lives saved with ticagrelor vs clopidogrel. To explain the surprise of this massive effect size, they compared it to the COMMIT trial of clopidogrel vs placebo in patients with acute MI. In COMMIT, 119 lives were saved with clopidogrel (vs placebo), but COMMIT had three-fold more patients than PLATO—and the gain was vs placebo. They tempt the reader to ask: how could ticagrelor fare that well against a drug that crushed placebo? We note two other reasons to be concerned about the outsized mortality reduction in PLATO. One is plausibility. The all-cause mortality benefit exceeded the reduction in MI, CV death or stroke. Given the numerically higher rate of bleeding, how else does ticagrelor reduce death vs clopidogrel? The second reason is the lack of such a signal in Phase 2 studies, such as this one. 5. PLATO results are on outlier: Multiple observational studies have failed to replicate the benefits of ticagrelor observed in the PLATO trial. While observational studies are inherently limited by confounding factors and are inferior to randomized trials, their findings warrant a re-evaluation of ticagrelor's benefits. Furthermore, two randomized trials—one conducted predominantly in Japanese patients and another in South Korea—did not demonstrate the superiority of ticagrelor, instead showing higher bleeding rates and a numerical increase in ischemic events.Ticagrelor also significantly underperformed against another new antiplatelet drug, prasugrel. In the non-industry-funded ISAR-REACT 5 trial, which enrolled patients with acute coronary syndrome, the primary event of death, MI, or stroke was 36% higher in the ticagrelor arm (9.3% vs 6.9%, HR 1.36, 95% CI: 1.09 - 1.70). Major bleeding was also numerically higher in the ticagrelor arm. 6. PLATO authors have responded to these arguments.We provide links to four of the authors responses. * Thrombosis and Hemostasis https://www.wellesu.com/10.1160/TH11-03-0162* Stroke https://www.ahajournals.org/doi/10.1161/strokeaha.111.000514* Inter J of Cardiol https://doi.org/10.1016/j.ijcard.2014.06.029* Circulation https://doi.org/10.1161/CIRCULATIONAHA.111.047498Conclusion These are vitally important revelations regarding PLATO and ticagrelor. The FDA advisory committee recommended that FDA require a confirmatory trial. This was not done. As such, ticagrelor gained serious market share in the non-clopidogrel antiplatelet market for more than a decade. Yet no other compelling evidence for its benefit over clopidogrel has come to light. It clearly underperformed vs prasugrel. These old and new revelations have changed our positive view of ticagrelor. We no longer have confidence in this drug. We strongly agree with the recommendation for another properly controlled trial. We also believe this highlights the benefits of having either two regulatory trials or a single regulatory trial combined with a mandated post-approval trial. These revelations also emphasize the benefits of robust critical appraisal and skeptical but not cynical approaches to surprising evidence. Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.Launch Date: December 12, 2024Release Date: December 12, 2024Expiration Date: November 30, 2025FACULTYGuy Young, MDProfessor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips-in-hemophilia-cutting-edge-advances-presented-at-ash-2024-1

In this week's episode we'll discuss HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Next, we'll learn about how 4D intravital imaging in mice reveals the key role of platelets as a source of procoagulant membranes in hemostasis. Finally, we'll hear about modifications to a common induction and maintenance treatment for treatment-naïve mantle-cell lymphoma.Featured ArticlesHA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem celltransplantation4D intravital imaging studies identify platelets as the predominant cellular procoagulant surface in a mousehemostasis modelRandomized study of induction with bendamustine-rituximab ± bortezomib and maintenance withrituximab ± lenalidomide for MCL

In this podcast, hear expert perspectives on practice-changing advances in the treatment and personalized management of patients with hemophilia from Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology/Oncology, and Professor of Pediatrics at Keck School of Medicine of USC; and Dr. Jennifer Davila, Co-Director of the Hemophilia Treatment Center at Montefiore and Associate Professor of Pediatrics at The Children's Hospital at Montefiore. Listen to the episode now! Click here to claim your free CME/NCPD credit for this activity: https://bit.ly/4eQSbaL

View Activity Information…

In this episode, we discuss the latest recommendations for treatments for osteopenia and osteoporosis, including vitamin D and calcium, as well as bisphophonates and other medications. Then we discuss new literature about best methods for induction of labor and risks factors for uterine rupture during a trial of labor after Cesarean. We also discuss a new trial about late preterm antenatal steroids.Also we talk about a new article about mammalian menopause the evolutionary rolls of menopause and concealed ovulation (fun people, we know!) Finally, we answer a listener question about bleeding during surgery. 00:00:02 Treatment of Osteopenia and Osteoporosis00:14:40 Vaginal Birth After Cesarean Recommendations00:24:05 Effectiveness of Late Preterm Steroids00:35:49 Menopause and Evolution in Mammals00:41:05 Concealed Estrus and Weight Gain Recommendations00:47:56 Managing Surgical Hemostasis and BleedingFollow us on Instagram @thinkingaboutobgyn.

The world of association management is evolving, and Thomas Reiser, the executive director of the International Society on Thrombosis and Hemostasis, is at the forefront of this. Reiser sat down with Skift Meetings to share his insights on what is shaping the future of associations and events in a post-Covid-pandemic landscape. "The traditional membership value is diminishing," Reiser candidly reveals, pointing to the challenges facing associations worldwide. This captures the seismic shifts that have prompted organizations like ISTH to reassess and retool their value propositions to members. This episode covers: Reiser's varied and international career spans multiple association management roles, including his current role. He has implemented major shifts, including shifting from a biennial to an annual congress and insourcing almost all event-related roles. We discuss the importance of the real role of medical societies, which is ultimately to improve people's lives We delve into the importance of public-facing initiatives such as World Kidney Day and World Thrombosis Day, both of which Tom was involved in launching. How Tom and ISTH work with suppliers as consultants and true partners And finally we look at the key trends that Tom sees as the biggest challenges and opportunities. Head to www.skiftmeetings.com to explore our daily news coverage and free-to-access reports and events.

Matt Zachek holds a Bachelor's degree and PhD in biomedical engineering and is currently the Sr Director of R&D at Werfen, leaders in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. Skilled in product roadmapping, stakeholder management, and product delivery in the medical device, pharmaceutical and diagnostic device spaces, Matt is a strategic thinker with a passion for bringing new ideas to life and a talent for fostering a culture of collaboration and creativity.Aaron Moncur, hostAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Today we want to unravel the intricate relationship between anticoagulants and regional anesthesia. Join Garry and Terry as they navigate through the delicate balance of benefits and risks associated with these practices. We'll dive into the world of anticoagulation reversal agents, discussing FDA-approved options such as Idarucizumab and Andexanet. So join Garry and Terry as they navigate the complexities of anticoagulants and regional anesthesia, emphasizing the critical role guidelines play in ensuring patient safety in the ever-evolving landscape of anesthetic practices.   Here's some of what we discuss in this episode: The evolving perspectives on NSAIDs, COX-2 inhibitors, and aspirin, emphasizing recent data that challenges initial concerns about spinal hematomas. Neuraxial anesthesia, celebrated for positive outcomes, brings its own set of risks, notably bleeding and hematoma formation. Heparin administration, both subcutaneous and intraoperative, prompts nuanced considerations, ensuring safety in the neuraxial procedure. Insights into thrombolytic therapy, urging caution due to limited clinical data.   Visit us online and get show resources here: https://beyondthemaskpodcast.com/   Get the CE Certificate here: https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf   Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246

On today's episode we'll discuss the prognostic significance of the ETP phenotype in children with T-cell ALL, address knowledge gaps in the management of chronic granulomatous disease and learn about the effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders.

Looking for more information on this topic? Check out the Congenital Disorders of the Urinary System brick. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/ from our Musculoskeletal, Skin, and Connective Tissue collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023Expiration Date: October 31, 2024 FACULTY BIOSAngela Weyand, MD   Associate Professor of MedicineUniversity of Michigan Medical SchoolGuy Young, MD      Professor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023Expiration Date: October 31, 2024 FACULTY BIOSAngela Weyand, MD   Associate Professor of MedicineUniversity of Michigan Medical SchoolGuy Young, MD      Professor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023Expiration Date: October 31, 2024 FACULTY BIOSAngela Weyand, MD   Associate Professor of MedicineUniversity of Michigan Medical SchoolGuy Young, MD      Professor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023Expiration Date: October 31, 2024 FACULTY BIOSAngela Weyand, MD   Associate Professor of MedicineUniversity of Michigan Medical SchoolGuy Young, MD      Professor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

August 11, 2023 Ray, Mark, and Scott discuss 2 questions that came into the Urology Coding and Reimbursement Group (see below for a link to sign up free):Good Evening Our office is looking into Chronic Care Management. We know that CCM requires the patient to have 2 chronic conditions. Most of these patients have prostate cancer and diabetes, and or hypertension. Which brings me to my question our providers will be treating and managing the cancer but as for as the diabetes goes they are not treating this or managing it in any way. Would we still be able to use this in out CCM billing?Hi, What CPT code set would you bill for Excision Scrotal Lesion(s)? (Path Report: Benign). Would you code with 11420-11426 or 11106-11107 or 54060 or something else? NOTE DETAILS: FINDING(s): Numerous scattered superficial skin lesions, In total 20cm skin removed. "We began by marking out the areas of concern with elliptical incisions. There were numerous lesions but they were spread out enough that we decided to do multiple separate incisions. After the lesions were marked the skin was anesthetized with 0.5% Macaine. Incisions were made sharply along the previous marked ellipse. The skin was then carefully dissected sharply from of the underlying dartos tissue. Hemostasis was achieved with bipolar cautery. This was repeated for all lesions."Urology Documentation, Coding, and Billing CertificationFor Urologists and APPs (Click Here for Pricing, More Information, and Registration)Documentation, Coding, and Billing Fellowship - Urology (DCB-FS) For Coders, Billers, and Admins (Click Here for Pricing, More Information, and Registration)Documentation, Coding, and Billing Specialist Certification (DCB-SC)Documentation, Coding, and Billing Master Certification (DCB-MC)Urology Advanced Coding and Reimbursement SeminarClick Here to Register Now  Las Vegas, December 1 & 2, 20238 am - 4:30 pm Friday, 8 am - 3:30 pm SaturdayNew Orleans, January 26 & 27, 20248 am - 4:30 pm Friday, 8 am - 3:30 pm SaturdayReserve your spot and save!As a Urology Coding and Reimbursement Podcast listener, you get access to a discount (limited-time offer).Use code: 24UACRS733Get signed up today and get peace of mind knowing you will be prepared for all the upcoming changes.The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ Join the discussion:Urology Coding and Reimbursement Group - Join for free and ask your questions, and share your wisdom.Click Here to Start Your Free Trial of AUACodingToday.com 

Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?

Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?

Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?

For paramedics, click HERE for CAPCE credits! The next frontier in Prehospital medicine is prehospital blood use.  The AABB (formerly the American Association of Blood Banks) is an international authority on transfusion medicine and tissue banking. The Trauma, Hemostasis and Oxygenation Research (THOR) Network is an international multidisciplinary network of civilian and military providers.  Together AABB-THOR has been working to achieve the dream of utilizing prehospital blood.  In our June Deep Dive, we discuss the manuscript:  THOR-AABB Working Party Recommendations for a Prehospital Blood Product Transfusion Program  with guest authors Christopher Winckler MD & Mark Yazer MD Click here to download it today! As always THANK YOU for listening. Hawnwan Philip Moy MD (@pecpodcast) Scott Goldberg MD, MPH (@EMS_Boston) Jeremiah Escajeda MD, MPH (@jerescajeda) Joelle Donofrio-Odmann DO (@PEMems) Maia Dorsett MD PhD (@maiadorsett) Lekshmi Kumar MD (@Gradymed1) Greg Muller DO (@DrMuller_DO) Works Discussed Newberry, R., Winckler, C. J., Luellwitz, R., Greebon, L., Xenakis, E., Bullock, W., ... & Mapp, J. (2020). Prehospital transfusion of low-titer O+ whole blood for severe maternal hemorrhage: a case report. Prehospital Emergency Care, 24(4), 566-575. https://www.tandfonline.com/doi/abs/10.1080/10903127.2019.1671562 THOR (Trauma Hemostasis and Oxygenation Research Network Website: https://rdcr.org/ Zhu, C. S., Pokorny, D. M., Eastridge, B. J., Nicholson, S. E., Epley, E., Forcum, J., ... & Jenkins, D. H. (2019). Give the trauma patient what they bleed, when and where they need it: establishing a comprehensive regional system of resuscitation based on patient need utilizing cold‐stored, low‐titer O+ whole blood. Transfusion, 59(S2), 1429-1438. https://onlinelibrary.wiley.com/share/ZCET9NGYI2GRV8ZF8WNH?target=10.1111/trf.15264

In this episode, we talk to Ariela Marshall, a hematologist specializing in disorders of thrombosis and hemostasis (bleeding and clotting) in women. In this interview, we discuss blood thinners, the role of estrogen in blood clots and disorders of thrombosis and hemostasis throughout a woman's life.Remember to like, rate and subscribe and enjoy the episode!Guest bioDr. Marshall is a hematologist specializing in disorders of thrombosis and hemostasis (bleeding and clotting) in women.  She is a graduate of Harvard Medical School and completed her residency in Internal Medicine at the University of Pennsylvania followed by a fellowship in hematology-oncology at Dana Farber Cancer Institute/Massachusetts General Hospital.  She worked as a hematologist at Mayo Clinic in Rochester Minnesota from 2015-2021 and in 2021 she moved to Philadelphia to became the Director of Women's Thrombosis and Hemostasis at the University of Pennsylvania.  Dr. Marshall is currently planning to move back to Minnesota in summer 2023 and will establish educational platforms and advocacy initiatives centered on women's health, particularly women's blood disorders.  In addition to her clinical work, Dr. Marshall is a medical educator with a focus on career development, leadership, mentorship, and work-life integration.  She has a particular interest in gender equity for patients as well as for physicians.  She leads several national advocacy initiatives, co-chairs several national working groups and task forces, and speaks regularly on a national scope to discuss her efforts to advance fertility/infertility awareness, parental health, and gender equity.  FemTech Focus Podcast bioThe FemTech Focus Podcast is brought to you by FemHealth Insights, the leader in Women's Health market research and consulting. In this show, Dr. Brittany Barreto hosts meaningfully provocative conversations that bring FemTech experts - including doctors, scientists, inventors, and founders - on air to talk about the innovative technology, services, and products (collectively known as FemTech) that are improving women's health and wellness. Though many leaders in FemTech are women, this podcast is not specifically about female founders, nor is it geared toward a specifically female audience. The podcast gives our host, Dr. Brittany Barreto, and guests an engaging, friendly environment to learn about the past, present, and future of women's health and wellness.FemHealth Insights bioLed by a team of analysts and advisors who specialize in female health, FemHealth Insights is a female health-specific market research and analysis firm, offering businesses in diverse industries unparalleled access to the comprehensive data and insights needed to illuminate areas of untapped potential in the nuanced women's health market.Time Stamps[04:10] Ariela's background[06:00] Definitions - hematology, hemostasis and thrombosis[07:52] How does bleeding and clotting affect women?[09:25] Disorders in younger women[11:50] Contraception[13:06] Blood clots[20:39] Blood thinning[22:58] Sex specific recommendations [24:24] The role of estrogen in blood clots[30:40] Bleeding and risk factors for menopausal women[32:33] Bleeding PSA's for women's health[36:48] What's an area of women's health and wellness that still needs innovating?[38:03] Insurance for blood thinners[38:58] What does the femtech industry as a whole need the most right now in order to be successful?[39:37] Are medical schools starting to have the conversation about sex as a biological variable?Call to Action!Don't forget to subscribe to the FemTech Focus podcast, and leave us a review!Episode ContributorsDr. Ariela MarshallLinkedIn: @Ariela Marshall, MDTwitter: @AMarshallMD Dr. Brittany BarretoLinkedIn:  @Brittany Barreto, Ph.D.Twitter: @DrBrittBInstagram: @drbrittanybarreto FemTech Focus PodcastWebsite: https://femtechfocus.org/LinkedIn: https://www.linkedin.com/company/femtechfocusTwitter: @FemTech_FocusInstagram: @femtechfocus FemHealth InsightsWebsite: https://www.femhealthinsights.com/LinkedIn: @FemHealth Insights

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this episode, to coincide with International Womens Day (March 8th), we are focusing on Gender equality in the workforce, why this is good for business and good for society overall. We meet with Eva Ohlsson Desormonts, Group HR Director for Stago and Amandine Serret International Business Support and Communications Director for Stago as well as an Executive Coach. Literature sources: Women in the Workpace 2022, McKinsey & Company whitepaper Challenges facing early career women in thrombosis and hemostasis—meeting the needs of the next generation, Guest Editorial, J Thromb Haemost. 2022;20:2453-5455   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Listen in as Dr. Caprini shares how he helped invent a device that helped save Marcus' life. Dr. Joseph Caprini, a vascular surgeon, shares how a disappointing military assignment spurred a career studying blood and vascular medicine. What's it like to have something named after you? Tune in and find some inspirational stories of how being open can lead to more compassionate interactions.Key topics:00:00 – Introductions00:46 – Dr. Joe Caprini reflects on how Marcus' speech, and experience, has affected his practice.04:30 – Marcus asks Joe about his motivation in joining healthcare and becoming a Doctor. 09:00 – Marcus and Joe talk about compassion and inspiring good patient care. 13:15 – Joe talks about his military medical career and his research into bleeding disorders.20:04 – Marcus follows up and asks about Squeezy Boots and shares his experience with them. 22:27 – Joe talks about a higher power and how things have aligned to help so many people. 29:08 – Marcus asks his rapid-fire questions. Joe wants to leave the audience with: “Just love everyone, I'll sort the rest out later. -signed God.”31:16 – Thank you and conclusions! Resources for you: More communication tips and resources for how to cultivate compassion: https://marcusengel.com/freeresources/Learn more about the Caprini Risk Score: www.capriniriskscore.org Connect with Dr. Caprini on Twitter: @caprinijosephConnect with Dr. Caprini on YouTube: https://www.youtube.com/c/venousresourcecenter Connect with Marcus on LinkedIn: https://www.linkedin.com/in/marcusengel/ Learn more about Marcus' Books: https://marcusengel.com/store/ Subscribe to the podcast through Apple: https://bit.ly/MarcusEngelPodcast Subscribe to the podcast through Spotify: https://bit.ly/Spotify-MarcusEngelPodcast More About Joseph A. Caprini, MD:Joseph A. Caprini, MD, is a Senior Clinician Educator at the Pritzker School of Medicine at the University of Chicago. He is also an Emeritus physician at NorthShore University HealthSystem, Evanston, IL. Dr. Caprini has authored or co-authored more than 480 articles, book chapters, and abstracts on the study and treatment of venous thromboembolism, venous insufficiency, and related topics. He has delivered more than 1800 lectures worldwide on a variety of topics including venous thromboembolism, laparoscopic surgery, wound care, and compression therapy. His society memberships include the International Society on Thrombosis and Hemostasis and the American Venous Forum, where he is a Distinguished Fellow and served as President 2009-2010.  He is a Distinguished Fellow of the Society for Vascular Surgery, a Founding Member and the first Honorary Fellow of the European Venous Forum, a Fellow of the American College of Surgeons and a member of the American Society of Hematology. He is Co-chair of the Technical Advisory Panel of JCAHO (2005 to date). He received the 2021 Founders Award from the American Venous Forum, and a lifetime achievement award from the Charing Cross Symposium in 2021. He worked with a group of scientists including Dr. Juan Arcelus to develop a DVT Risk Assessment protocol, which has been validated in more than 5 million patients, involving more than 300 peer reviewed publications, used in many countries across the globe. The score can be calculated and downloaded on the website www.capriniriskscore.org. This site contains his videos (110 to date), and all 310 citations and abstracts for articles using the Caprini Risk Score.  The list is updated weekly from PubMED.Date: 3/6/2023Name of show: Compassion & Courage: Conversations in HealthcareEpisode title and number: Episode 92 – Dr. Joe Caprini - The Compassion of In-Laws

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, we are delighted to speak to April Matera. April experienced a stroke at the age of 39 and from there began her journey towards an anti-phospholipid syndrome diagnosis. Unfortunately it took 7 different visits to 7 different doctors to get her there. She tells us here about her APS road and how it has impacted her life and her dream to have a family.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

In this episode of the JIM Podcast, Editor-in-Chief Richard McCallum speaks with Dr. Mateo Porres-Aguilar about thrombosis and anticoagulants. Dr. Porres-Aguilar is a current Fellow of the American College of Physicians (FACP), he holds a National Board Certification of Anticoagulation Care Providers in the USA (NCBAP), is an academic Member of the International Society for Thrombosis and Heamostasis (ISTH), and he currently serves as an international representative in North America for the Mexican Society of Thrombosis and Hemostasis (SOMETH), and is part of the Latin-american chapter of Venous Thrombosis for the Latin-American Collaborative Group for Hemostasis and Thrombosis (Grupo CLAHT)

In this episode we interview two of the authors of a recent paper, Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH, Dr Maha Othman and Dr Leonardo Brandao on this paper from the Journal of Thrombosis and Haemostasis. 2022;20:1735–1743. Severe congenital protein C deficiency (SCPCD) is rare and there is currently substantial variation in the management of this condition. A joint project by three Scientific and Standardization Committees of the ISTH was developed to review the current evidence and help guide on diagnosis and management of SCPCD.About our guests:Dr. Maha Othman is a clinical pathologist/hematologist with specialized training in haemostasis laboratory testing and molecular genetics of bleeding disorders. She obtained her medical degree and MSc in Clinical Pathology in Mansoura University in Egypt. She then completed her PhD in Pathology from Southampton University, UK. After this, she pursued post-doctoral research training in molecular genetics of hemophilia and von Willebrand disease with Dr. David Lillicrap, at Queen's University, Canada. Dr. Othman is currently a full Professor at the School of Medicine, Queen's University and at St Lawrence College, Kingston, Ontario. Her research interests include the clinical and molecular aspects of von Willebrand disease and platelet disorders particularly PT-VWD, and thromboelastography assessment of coagulopathies in women, pregnancy and cancer. She has more than 100 research papers and her research is recognized internationally. She is an editor for Seminars in Thrombosis and Haemostasis and Research and Practice in Thrombosis and Haemostasis Journals. She is a reviewer for a number of Haemostasis journals and a member of several scientific organizing committees on women's health, and advisory boards for international haemostasis conferences. She is the previous Chairman of the Scientific and Standardization Committee (SSC) on Women's Health Issues in Thrombosis and Haemostasis of the ISTH and currently CO-Chair on the SSC for DIC. She is a passionate educator and mentor and an advocate for rare bleeding disorders and bleeding and clotting disorders in women.Dr. Leonardo Brandão  is a native Brazilian who joined the staff at The Hospital for Sick Children in 2004. Since 2019, he has been the Thrombosis Program director. He obtained his medical degree at the University of São Paulo (USP) School of Medicine (FMUSP) before moving to North America, where he completed his post-graduate training (Paediatrics Residency at Emory University, Atlanta/GA, Paediatric Haematology/Oncology fellowship at St. Jude Children's Research Hospital, Memphis/TN, and a second fellowship in Paediatric Coagulation at Weill Cornell University, New York/NY). After finishing his training, he moved to Canada to focus on the field of paediatric thrombosis at SickKids. He is the past-chair of the thrombosis committee for the Canadian Pediatric Thrombosis Hemostasis Network (CPTHN), past-Canadian representative-elect for the Hemostasis and Thrombosis Research Society (HTRS), past-member of the first paediatric venous thromboembolism panel for the American Society of Hematology (ASH), past-co-chair of the paediatric thrombosis subcommittee for the International Society on Thrombosis and Hemostasis (ISTH), and a member of Thrombosis Canada. Links:Thrombosis Canada Clinical Guide:Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In this series of our new season we will be covering Womens' health and looking at the broader implications of coagulation and then speaking to a Lupus patient advocate on the impact this disease has had for her personally. To start off, in today episode, we are delighted to speak to our Clinical Development Director, Dr Francois Depasse about the broader connection between Womens' Health and coagulation and then a more in depth look at APS. Links to related podcasts: S1E13 - Lupus anticoagulant diagnosis work-up https://www.podcastics.com/podcast/episode/13-the-lupus-anticoagulant-diagnosis-work-up-54015/ S3E7 - Hemostasis results interpretation along pregnancy https://www.podcastics.com/podcast/episode/s3e7-hemostasis-results-interpretation-along-pregnancy-134753/ Literature sources: https://www.cdc.gov/ncbddd/blooddisorders/women/facts.html Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306 Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 809-813 CLSI Laboratory testing for the Lupus anticoagulant - Approved Guideline. CLSI document H60-A. Wayne, PA; 2014. Devreese, KMJ, de Groot, PG, de Laat, B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18: 2828– 2839. https://doi.org/10.1111/jth.15047    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

In this episode, host Alyssa Watson, DVM, is joined by Armi Pigott, DVM, DACVECC, to talk about his recent Clinician's Brief article, “Drugs & Blood Products Used to Manage Bleeding Disorders.” Hemostasis can be complicated, but Dr. Pigott helps to break it down into its 3 phases, then uses those to organize diseases and treatments. He also discusses practical details about blood products and transfusions.Resource:https://www.cliniciansbrief.com/article/drugs-blood-products-used-manage-bleeding-disordersContact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Digital Content CoordinatorRandall Stupka - Podcast Production & Sound Editing

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Professor Romaric Lacroix will explain us how fibrinolysis is important to the whole hemostasis process and how the sample fibrinolytic activity needs to be evaluated and sometimes monitored. Link to previous podcasts: S1E15 – Disseminated Intravascular Coagulation (DIC) and fibrin related markershttps://www.podcastics.com/podcast/episode/15-disseminated-intravascular-coagulation-dic-and-fibrin-related-markers-54016/   Literature sources: Cointe S, Vallier L, Esnault P, Dacos M, Bonifay A, Macagno N, Harti Souab K, Chareyre C, Judicone C, Frankel D, Robert S, Hraiech S, Alessi MC, Poncelet P, Albanese J, Dignat-George F, Lacroix R. Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock. Blood. 2022 Apr 14;139(15):2377-2391. Cointe S, Harti Souab K, Bouriche T, Vallier L, Bonifay A, Judicone C, Robert S, Armand R, Poncelet P, Albanese J, Dignat-George F et Lacroix R. A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance. J Extracell Vesicles 2018; Jul 16;7(1):1494482 Vallier L, Cointe S, Lacroix R, Bonnifay A, Judicone C, Dignat-George F, Hau C. Kwaan. Microparticle and fibrinolysis. Semin Thromb Hemost. 2017 Mar;43(2):129-134   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

In this episode, we break down the initial approach to the evaluation of a patient with a suspected bleeding disorder, particularly in regards to hemophilia, including standardized bleeding assessment tools, the basics of the coagulation cascade, and mixing studies. The first step is taking a thorough bleeding history:The Fellow on Call Bleeding Assessment: 1. Mucosal bleeding working from nose down: epistaxis (did they need cauterization), gum bleeding, bleeding with tooth pulling, hematochezia, hematuria, menorrhagia or excessive post-partum bleeding2. Skin: Bruising, petechiae, telangiectasias 3. “Ortho bleeding”: spontaneous joint or muscle hematoma (raises concern for hemophilia) 4. Prior surgical or family history?5. Medications? Always clarify: are these issues lifelong?The International Society for Thrombosis and Hemostasis scoring tool is useful for standardizing bleeding symptoms, and it can help you determine the likelihood that a patient has an underlying bleeding disorder.Physical exam: Pay particular attention to: * Assess skin for bruising or petechiae* Assess the fingertips* If having epistaxis, may need to have help to assess nostrils for anatomical issues (vessels)* Assess mucosal surfaces for telangiectasias which could point to a diagnosis of Hereditary Hemorrhagic Telangiectasia, a mimicker of bleeding disorders* Assess thighs and flanks for obvious signs of bruising/bleedingWe sort bleeding disorders into two large buckets:* Platelet dysfunction → minor bleeding (i.e., mucosal bleeding, epistaxis) * Factor deficiency → major bleeding (i.e., joint effusions, spontaneous ICH) The basic workup includes: * CBC - to assess for low platelets * Peripheral smear - rule out schistocytes (DIC)* CMP - to check for liver dysfunction or severe renal dysfunction/uremia which leads to platelet dysfunction * PT/INR, aPTT, fibrinogen* Von Willebrand PanelCoagulation Cascade: * PT → measures the extrinsic pathway → factor 7 (lucky) * PTT → measures the intrinsic pathway → factors 12, 11, 9, 8 (TENET)* Intrinsic and extrinsic pathway feed into the common pathway → factors 10, 5, 2, 1 (All dollar bills less than $20) If a patient has an abnormal PT/PTT, you must ask: is it a lack of a necessary clotting factor or something interfering with the time it takes a clot to form? You assess this with a mixing study.* A mixing study combines equal parts of the patient's plasma with control plasma. * Mixing study corrects → deficiency of a coagulation factor * Mixing study does not correct → antibody interfering with assay or the function of the factors in the coagulation cascade **To correct, the time must be in the normal range for the assay, not just slightly improved!**The mixing study is assessed at time points 0 hr, 1 hr, 2 hr; the presence of an inhibitory may improve the time initially, but can then become longer again at time points 1hr and/or 2hrAfter the mixing study, then you also need to know which of the factors is the issue! How to do this: * Functional assays can be ordered to measure individual coagulation factor function.* Factor 11 – Hemophilia C* Factor 9 – Hemophilia B* Factor 8 – Hemophilia A * Understanding the coagulation cascade allows you know quickly know what to orderReferences:https://bleedingscore.certe.nl: ISTH/SCC Bleeding Assessment Toolhttps://ashpublications.org/ashclinicalnews/news/2436/How-I-Teach-the-Coagulation-Cascade: “How I Teach the Coagulation Cascade” by Dr. Alice Ma at University of North CarolinaLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.   Link to previous podcasts: S1E11 – How to be more productive (part 1): implementation of a rules engine  S2E8 - World Hemophilia Day  S2E4 - How to determine factor levels in hemophilia?  Literature sources: Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology). Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63 Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8. Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463). Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72 Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18. Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Gabrielle Pearl will explain us the particularities of thrombosis and hemostasis in pediatric population, and how to manage pediatric patient samples in the clinical laboratory. Link to previous podcasts: S2E5 - How to collect and prepare the coagulation samples properly? S2E3 - How to establish and control the reference range of my assay?   Literature sources: Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De Rosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006 Feb;95(2):362-72. doi: 10.1160/TH05-01-0047. Monagle P, Massicotte P. Developmental haemostasis: secondary haemostasis. Semin Fetal Neonatal Med. 2011 Dec;16(6):294-300. doi: 10.1016/j.siny.2011.07.007. Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 2013; 11: 1850–4. Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr. 2006 Aug;149(2):275-7. doi: 10.1016/j.jpeds.2006.04.008 Lippi G, Franchini M, Montagnana M, Guidi GC. Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost. 2007 Nov;33(8):816-20. doi: 10.1055/s-2007-1000373.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice

Two of the co-authors (Dr Jameel Abdulrehman and Dr Leslie Skeith) of the recently published review and meta-analysis, "Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis" (https://doi.org/10.1111/bjh.18331) discuss the clinical relevance of the results and implications for managing risk for women who have experienced a VTE while on combined oral contraceptives. Dr. Jameel Abdulrehman is a Hematologist and clinician investigator with specialization in Thrombosis and Hemostasis at the Toronto General Hospital within the University Health Network and assistant professor at the University of Toronto. He completed medical school at the University of Alberta, Internal Medicine residency at Western University, Hematology residency at the University of Alberta, a fellowship in thrombosis and hemostasis at the University of Toronto, and a masters in clinical epidemiology at McMaster University. He is an early career investigator with research interests in clinical studies in the use anticoagulation in special populations. He is also the regular co-host of this podcast. And Dr Leslie Skeith:Dr. Leslie Skeith is a Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her medical school and Hematology residency training at the University of Calgary, and completed a 2-year fellowship in Thrombosis Medicine at the University of Ottawa. Dr. Skeith's research interest is in the area of pregnancy and venous thromboembolism, as well as medical education. She is currently completing a Master of Health Professions Education (MHPE) degree at the University of Chicago at Illinois (UIC).Follow us:@thrombosiscan@leslieskeithReference:Abdulrehman J, Elbaz C,Aziz D, Parpia S, Fazelzad R, Eischer L, et al. Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and metaanalysis. Br J Haematol. 2022;00:1–13. https://doi.org/10.1111/bjh.18331Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode, host Shikha Jain, MD, speaks with hematologist, medical educator and University of Pennsylvania director of the women's thrombosis and hemostasis program, Ariela Marshall, MD, about fertility advocacy for patients and physicians, navigating the medical system as physician parents and more. Welcome to another exciting episode of Oncology Overdrive :14 About Marshall :18 The interview: 1:44 How did you get involved and interested in doing the work in the fertility space, and what led you to that world? 3:02 Do you think that some of this is due to the fact the way our healthcare system is set up in a way where women's symptoms are often disregarded, or the way we look at our patients is riddled with implicit bias? Why do you think that this is such a huge problem? 7:30 What has been your experience with physicians and physician infertility? … Is it something that we have ideas of how we can really move the needle and change this? 11:26 Have you noticed any sort of culture shift, or do you think we still have a really long way to go in that space? 17:38 Creating and normalizing an office environment where family is a priority 22:48 Cultures and responses to reproductive health in the physician workforce 29:03 How the overturning of Roe v. Wade is going to impact infertility and fertility treatment 32:06 Is there hope for the future when we talk about these things? … Looking at the data, is this something that we can strive for or may change? 21:03 What are your future plans for this type of work and your research? What are you thinking the next steps are going to be? 26:48 If somebody could only listen to 2 minutes of today's episode, what would you want them to take away? 39:56 How to contact Marshall 41:16 Thanks for listening 43:00 Ariela Marshall, MD, is a hematologist, medical educator and the director of the Women's Thrombosis and Hemostasis program at University of Pennsylvania in Philadelphia, Pennsylvania.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Marshall can be reached on Twitter @AMarshallMD. Disclosures: Jain and Marshall report no relevant financial disclosures.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today episode, our expert Lydie Nicoud, R&D reagent manager, will talk with us about the test of fibrinogen.  As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it. Literature sources: Miesbach W, Schenk J, Alesci S, Lindhoff-Last E, Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia .Thromb Res. 2010; 126(6): e428-33 Karapetian H. Reptilase time (RT). Methods Mol Bio 2013; 992:273-7. Mackie IJ, Kitchen S, Machin SJ, Lowe GDO, Guidelines on fibrinogen assays, Br J Hematol 2003; 121: 396-404 Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD. External quality assurance of fibrinogen assays using normal plasma: results of the 2008 College of American Pathologists proficiency testing program in coagulation. Arch Pathol Lab Med. 2012 Jul;136(7):789-95. doi: 10.5858/arpa.2011-0322-OA. PMID: 22742551.Siriez R, Dogné JM, Gosselin R, Laloy J, Mullier F, Douxfils J Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 2021; 43(1): 7-20   Related podcasts: S1E9: How to manage HIL samples in the coagulation laboratory?  S1E15: Disseminated Intravascular Coagulation (DIC) and fibrin related markers.  S2E6: Prothrombin Time routine does not mean "simple".    S2E7: APTT, not a one-for-all purposes reagent.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

This recording features audio versions of September 2022  Journal of Vascular and Interventional Radiology (JVIR) abstracts:Uterine Artery Embolization for Pedunculated Subserosal Fibroids: A Systematic Review and Meta-Analysis ReadMicrowave Ablation as Bridging to Liver Transplant for Patients with Hepatocellular Carcinoma: A Single-Center Retrospective Analysis ReadPhase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies ReadPredictors of Major Hemorrhage After Spleen Core Biopsy in Cancer Patients ReadThe Use of an Inflatable Adhesive External Compression Device for Maintenance of Hemostasis following Angiography in Children ReadVascular Pathology and Impact of Stent Eccentricity for Stent Restenosis in Femoropopliteal Endovascular Therapy ReadPercutaneous Sclerotherapy for Budd-Chiari Syndrome Secondary to Giant Hepatic Venous Malformations (Hemangiomas) ReadJVIR and SIR thank all those who helped record this episode:Host:Daniel Kim, Edward Via College of Osteopathic Medicine, VirginiaAudio editor:Patrick Bryan, Rocky Vista University College of Osteopathic Medicine Southern Utah CampusAbstract readers:Jonathan Dzielski, Kansas City University, MissouriKonrad Kozlowski, University of Miami Miller School of MedicineAna Gonzalez, University of Illinois College of Medicine at ChicagoLyanne Lu, University of California at Davis School of MedicineRommell Noche, MS, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutJacob Knittel, Creighton University School of Medicine, Phoenix Regional CampusTalia Fradkin, MHA, Florida Atlantic University College of Medicine©  Society of Interventional RadiologySupport the show

Looking for more information on this topic? Check out the Congenital Disorders of the Urinary System brick. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/ from our Musculoskeletal, Skin, and Connective Tissue collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.

Jordan Shavit is a professor of Pediatrics and Human Genetics, and the Henry and Mala Dorfman Family Professor at the University of Michigan. Dr. Shavit's research interests are the genetics of hematologic and cardiovascular diseases, including hemophilia and bleeding disorders, as well as excessive clotting, such as myocardial infarction, stroke, and deep vein thrombosis. He has used genome editing to produce mutations in the relevant pathways, with the surprising finding that fish tolerate disturbances that are embryonic lethal in mammals. Dr. Shavit is Vice President/President-Elect of the Hemostasis and Thrombosis Research Society, a recent chair of the Megakaryocyte and Platelet Scientific Subcommittee of the American Society of Hematology, and co-chair of the Hematology Research Interest Group of the Zebrafish Disease Models Society.

Nicole Spencer is a Clinical Field Engineer at Fiagon, an endoscopic sinus surgery medical device company. Before Fiagon, Nicole worked as an Integration Engineer at Epic, a healthcare software company. She is also a 2019 grad of the Joint Department of Biomedical Engineering at UNC and NC State. Nicole speaks on what it's like to be a Clinical Field Engineer, traveling and being in surgeries for work, and her experience with her company getting acquired by Hemostasis. More on The BME Grad Podcast: Follow us on LinkedIn: www.linkedin.com/company/thebmegradpodcast/ Follow us on Instagram: www.instagram.com/thebmegradpodcast/ Subscribe on YouTube: www.youtube.com/channel/UCyfF0xH80d5lS1RpQsmpw0Q/videos Connect with or reach out to Host, Allie Mitzak, on LinkedIn: www.linkedin.com/in/allie-mitzak Connect with, or reach out to Host, Brian Kim, on LinkedIn: www.linkedin.com/in/briandonginkim/

Nicole Spencer is a Clinical Field Engineer at Fiagon, an endoscopic sinus surgery medical device company. Before Fiagon, Nicole worked as an Integration Engineer at Epic, a healthcare software company. She is also a 2019 grad of the Joint Department of Biomedical Engineering at UNC and NC State. Nicole speaks on what it's like to be a Clinical Field Engineer, traveling and being in surgeries for work, and her experience with her company getting acquired by Hemostasis. More on The BME Grad Podcast: Follow us on LinkedIn: www.linkedin.com/company/thebmegradpodcast/ Follow us on Instagram: www.instagram.com/thebmegradpodcast/ Subscribe on YouTube: www.youtube.com/channel/UCyfF0xH80d5lS1RpQsmpw0Q/videos Connect with or reach out to Host, Allie Mitzak, on LinkedIn: www.linkedin.com/in/allie-mitzak Connect with, or reach out to Host, Brian Kim, on LinkedIn: www.linkedin.com/in/briandonginkim/

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.   In today's episode, our guest Dr Bryan G Fry, aka Venom Doc, will make us enter his world and understand how venom interact with coagulation and how they can prove useful for assay or drug design & development     Literature sources: Fry BG, Roelants K, Champagne DE, Scheib H, Tyndall JD, King GF, Nevalainen TJ, Norman JA, Lewis RJ, Norton RS, Renjifo C, de la Vega RC. The toxinogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu Rev Genomics Hum Genet. 2009, 10: 483-511. Bittenbinder, M. A., C. N. Zdenek, B. Op den Brouw, N. J. Youngman, J. S. Dobson, A. Naude, F. J. Vonk and B. G. Fry (2018). "Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)." Toxins (Basel) 10(12): 516. Chowdhury, A., M. R. Lewin, C. N. Zdenek, R. Carter and B. G. Fry (2021a). "The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms." Front Immunol 12: 752442. Seneci, L., C. N. Zdenek, A. Chowdhury, C. F. B. Rodrigues, E. Neri-Castro, M. Benard-Valle, A. Alagon and B. G. Fry (2021). "A Clot Twist: Extreme Variation in Coagulotoxicity Mechanisms in Mexican Neotropical Rattlesnake Venoms." Front Immunol 12: 612846. Chowdhury, A., C. N. Zdenek, J. S. Dobson, L. A. Bourke, R. Soria and B. G. Fry (2021b). "Clinical implications of differential procoagulant toxicity of the palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors." Toxicol Lett 340: 77-88. Chowdhury, A., C. N. Zdenek, M. R. Lewin, R. Carter, T. Jagar, E. Ostanek, H. Harjen, M. Aldridge, R. Soria, G. Haw and B. G. Fry (2021). "Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors." Frontiers in Immunology 12: 2251. Zdenek, C. N., B. O. den Brouw, D. Dashevsky, A. Gloria, N. Youngman, E. Watson, P. Green, C. Hay, N. Dunstan, L. Allen and B. G. Fry (2019a). "Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms." Toxicol Lett 316: 171-182. Zdenek, C. N., C. Hay, K. Arbuckle, T. N. W. Jackson, M. H. A. Bos, B. Op den Brouw, J. Debono, L. Allen, N. Dunstan, T. Morley, M. Herrera, J. M. Gutierrez, D. J. Williams and B. G. Fry (2019b). "Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom." Toxicol In Vitro 58: 97-109. Sousa, L. F., C. A. Nicolau, P. S. Peixoto, J. L. Bernardoni, S. S. Oliveira, J. A. Portes-Junior, R. H. Mourao, I. Lima-dos-Santos, I. S. Sano-Martins, H. M. Chalkidis, R. H. Valente and A. M. Moura-da-Silva (2013). "Comparison of phylogeny, venom composition and neutralization by antivenom in diverse species of bothrops complex." PLoS Negl Trop Dis 7(9): e2442. Rogalski, A., C. Soerensen, B. Op den Brouw, C. Lister, D. Dashevsky, K. Arbuckle, A. Gloria, C. N. Zdenek, N. R. Casewell, J. M. Gutierrez, W. Wuster, S. A. Ali, P. Masci, P. Rowley, N. Frank and B. G. Fry (2017). "Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies." Toxicol Lett 280: 159-170. Youngman, N. J., J. Llinas and B. G. Fry (2021). "Evidence for Resistance to Coagulotoxic Effects of Australian Elapid Snake Venoms by Sympatric Prey (Blue Tongue Skinks) but Not by Predators (Monitor Lizards)." Toxins (Basel) 13(9).   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest François Depasse will help us to understand the hemostasis results obtained along pregnancy, what are the related difficulties for the lab and Link to previous podcasts: S1E15 Disseminated Intravascular Coagulation (DIC) and fibrin related markers: S2E1 Whole Blood Viscoelastic Testing (VET) Literature sources: Szecsi PB, Jørgensen M, Klajnbard A, Andresen MR, Colov NP, Stender S, Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 2013: 718-27 Kristoffersen AH, Peters PH, Bjørge L, Røraas T and Sandberg S. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry 2019; 56(6): 692-700. Hellgren H. Hemostasis during normal prgenancy and puerperium. Semin Thromb Hemost. 2003; 29(2): 125-30. Leduc L, Wheeler JM, Kirshon B, Mitchell P, Cotton DB, Coagulation profile in severe preeclampsia, Obstet Gynecol 1992 79(1); 14-8 Gillissen A, van den Akker T, Caram-Deelder C, Henriquez DDCA, Bloemenkamp KWM, de Maat MPM, van Roosmalen JJM, Zwart JJ, Eikenboom J, van der Bom JG. Coagulation parameter during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. Blood Adv 2018; 2(19): 2433-42 Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumey F, Corouge I, Le Goueze A, Rackelboom T, Broisin F, Vial F, Luzi A, Capronnier O, Huissoud C, Mignon A, Early and systematic administration of fibrinogen concentrate in post-partum haemorrhage following vaginal delivery: the FIDEL randomized controlled trial. BJOG 2021. 128:1814-23. Brenner A, Ker K, Shakur-Still H, Roberts I. Tranexamic acid for post-partum haemorrhage: what, who and when. Best Pract Res Clin Obstet Gynaecol. 2019; 1:66-74   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

In October 2020, the University of Vermont Medical (UVM) Center fell victim to a cyberattack, and the leadership team intentionally shut down their system to prevent patient information from escaping the network. UVM Health was offline for 25 days. On this episode of Inside the Lab, our hosts, Ms. Kelly Swails and Mr. Mark Moen, are joined by Dr. Toby Cornish, MD, PhD, Associate Professor and Vice Chair of Pathology Informatics at the University of Colorado and Associate Editor for Informatics for AJCP; Dr. Andrew Goodwin, MD, FCAP, Medical Director for the Hemostasis and Thrombosis Laboratory and Vice Chair for Quality and Clinical Affairs; Dr. Christi Wojewoda, MD, FCAP, Clinical Microbiology Laboratory Director and Vice Chair for Education in the Department of Pathology and Laboratory Medicine; and Dr. Anne Stowman, MD, Dermatopathologist and Director of Surgical Pathology Operations, to discuss the ransomware attack.  Our panelists explain when they realized there was a significant issue with their system and what radical workflow changes they initiated to deal with being offline for 25 days. They describe the challenges particular to different departments at UVM and what their teams did to overcome them. Listen in to learn what YOU can do to prepare for a potential ransomware attack in your lab. Topics Covered · When UVM realized there was a significant problem with their system and the leadership team's initial response · Why the cyberattack only affected UVM's primary medical center and not its entire health network · The radical workflow changes UVM labs instituted during downtime and the support they received from other departments· What the UVM labs did to reduce the volume of specimens coming into the lab · The challenge UVM pathologists and laboratory professionals faced in delivering test results manually · How the experience in the clinical lab differed from that of the anatomic pathology department· The particular challenges faced in the microbiology and transfusion medicine labs at UVM during downtime· What alternative technologies the UVM labs leveraged to continue operating during downtime· Advice to pathologists and lab professionals on preparing for a cyberattackConnect with ASCPASCPASCP on Twitter Connect with Dr. CornishDr. Cornish on Twitter Dr. Cornish on LinkedIn Connect with Dr. GoodwinDr. Goodwin at the University of Vermont  Connect with Dr. Wojewoda Dr. Wojewoda on Twitter Dr. Wojewoda on LinkedInConnect with Dr. Stowman Dr. Stowman on LinkedIn Connect with Ms. Swails & Mr. MoenMs. Swails on Twitter Mr. Moen on LinkedInResources Inside the Lab in the ASCP Store  

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Daniel Pilbeam, from the Clinical Pathology Laboratory at UVet in Melbourne will help us understand the common points and differences between veterinary and human hemostasis, and what should be critically assessed.   Previous episodes in relation to the topic:  AskStago episode #9 (season 1): How to manage HIL samples in the coagulation laboratory?   Literature sources: John W. Harvey, Veterinary Hematology, Chapter 7 - Evaluation of Hemostasis: Coagulation and Platelet Disorders, W.B. Saunders, 2012, Pages 191-233, ISBN 9781437701739, https://doi.org/10.1016/B978-1-4377-0173-9.00007-5. Beurlet S, Coisnon C, Nguyen TT, Richet M, Carlo A, Briend-Marchal A. Comparison of STA-NeoPTimal (Stago) and STA-Neoplastine CI Plus (Stago) thromboplastin reagents using a STA Satellite Max analyzer to measure prothrombin times in dogs. Vet Clin Pathol. 2021 Sep;50(3):348-353. doi: 10.1111/vcp.12949. A previous pathologist, Bruce Parry, also co-wrote a paper that was instrumental in identifying cut offs for factor deficiencies that we still use the reference range for today.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Many patients living in rural America encounter unique boundaries to receiving the critical healthcare they need, particularly when faced with a rare disorder or disease. March is Bleeding Disorders Awareness Month, and Dr. Len Valentino is working to educate and advocate for upwards of 10,000 rural Americans living with a rare blood or bleeding disorder. “Understanding rural health is critical to serving the population of the US.” ~Dr. Len Valentino As CEO of the National Hemophilia Foundation, Dr. Valentino brings more than 35 years of clinical and research experience related to inheritable blood disorders to the organization. Prior to his most recent work with Spark Therapeutics, a biotech startup, he founded and led the Hemophilia and Thrombophilia Center at Rush University Medical Center in Chicago, where he successfully balanced a $10 million budget to support research grants, research, and clinical teams–keeping the patient and their families as his core focus. He earned his undergraduate and medical degrees from Creighton University and Creighton University School of Medicine.  He then completed the University of Illinois at Chicago's Pediatric Medicine Residency before completing a fellowship in pediatric hematology-oncology at the David Geffen School of Medicine at UCLA. Dr. Valentino remains an active member of multiple professional organizations, including The American Society of Hematology; International Society of Thrombosis and Hemostasis; Medical Affairs Professional Society; and The Hemophilia and Thrombosis Research Society To learn more, check out www.hemophelia.org

Ariela Marshall, MD, is the Director of the Women's Hemostasis and Thrombosis Program and the Associate Program Director of Non-Malignant Hematology fellowship at the University of Pennsylvania. She is an international leader and innovator in practice leadership and medical education with a passion for mentoring trainees into positions at top institutions. Dr. Marshall completed her medical school from Harvard Medical School, residency in Internal Medicine from the Hospital of University of Pennsylvania and a fellowship in Hematology/Oncology from Dana- Farber Cancer Institute at Harvard. Often, the most challenging aspect of life for a new physician is achieving some semblance of harmony between the demanding career of medicine and a fulfilling, passionate personal life. Is it realistic to expect one mentor to relate with who you are and aspire to become on a personal and professional level? Join us for this episode and learn why Dr. Ariela Marshall firmly believes that “it's rare to find a mentor for both your work and your life” and why you should be open to bringing mentors into your life that can each help you to overcome specific challenges. Pearls of Wisdom: 1. We need to discuss one problem or area of opportunity with one person rather than getting scattered. That's fundamental; rather than taking the same question to six people, find the one person who can offer the perfect solution. 2. Open up to your mentors. It doesn't have to be with everybody, but exerting effort to search for that person is essential; we'll be amazed at the similarities we'll discover between us. Despite feeling alone sometimes, we're not alone. 3. People exceeding your expectations are the people that you want to exceed expectations for.

Remember these terms? Hemostasis, Inflammation, Proliferation, and Tissue Remodeling? Here, we cover a brief overview of what these stages are all about so that we can understand what normal healing looks like in case we need to recognize when abnormal healing is taking place. The purpose of this podcast is to provide useful, condensed information for exhausted, time-crunched Physical Therapists and Student Physical Therapists who looking to build confidence in their foundational knowledge base and still have time to focus on other important aspects of life.  Hit subscribe to make sure you never miss an episode. Have questions? Want to connect? Contact me at ptsnackspodcast@gmail.com or check out more at ptsnackspodcast.com. Support the show (https://buymeacoffee.com/Ptsnackspodcast)